NCT03213145View on ClinicalTrials.gov

Drug-drug Interaction Study Between EDP-305, Intraconazole and Rifampin in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

July 11, 2017

Primary Completion Date

August 10, 2017

Study Completion Date

September 7, 2017

Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
DRUG

intraconazole

Subjects will receive itraconazole once daily from Day 5 through Day18

DRUG

Rifampin

Subjects will receive rifampin once daily from Day 5 through Day 16

DRUG

EDP 305

Subjects will receive EDP 305 once daily on Day 1 and Day 14

Trial Locations (1)

66219

Pharmaceutical Research Associates, Inc.,, Lenexa

Sponsors
All Listed Sponsors
lead

Enanta Pharmaceuticals, Inc

INDUSTRY

NCT03213145 - Drug-drug Interaction Study Between EDP-305, Intraconazole and Rifampin in Healthy Volunteers | Biotech Hunter | Biotech Hunter